» Articles » PMID: 36016982

Clinical Characteristics and Outcomes in Chronic Kidney Disease Patients with Tuberculosis in China: A Retrospective Cohort Study

Overview
Journal Int J Gen Med
Publisher Dove Medical Press
Specialty General Medicine
Date 2022 Aug 26
PMID 36016982
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The diverse manifestations of tuberculosis (TB) in chronic kidney disease (CKD) patients can cause difficulty in diagnosis, delayed treatment, even death. Therefore, this study investigated the clinical characteristics and the risk factors for mortality in CKD patients with TB.

Methods: This retrospective study included 167 patients diagnosed with active TB at two tertiary medical centers in Chongqing within six years. Clinical characteristics and outcomes of anti-TB treatment in patients with and without CKD were collected, and the predictive mortality values of variables were analyzed.

Results: Of the 167 patients, 66.7% (44/66) hemodialysis (HD), 41.1% (21/51) pre-HD, and 32.0% (16/50) non-CKD patients had extrapulmonary TB. The pleura and lymph node were the common sites in CKD patients. Clinical presentations of cough and hemoptysis in CKD patients were less common than those in non-CKD patients, 13.7% (16/117) of CKD patients even not having any clinical symptoms. The positive rates of tuberculin skin test, TB-polymerase chain reaction and acid-fast bacilli in sputum in HD patients were lower than those in pre-HD and non-CKD patients (<0.05). CKD patients were more prone to gastrointestinal and neurological side effects during anti-TB treatment. The mortality rates of non-CKD, pre-HD and HD patients was 6.1%, 31.9% and 37.3%, respectively. Multivariate Cox analysis revealed that age≥40 years (HR: 5.871; =0.019), hypoalbuminemia (HR:2.879; =0.004), CKD stage 4-5 (HR:4.719; =0.018) and HD (HR:6.13; =0.005) were associated with mortality.

Discussion: CKD patients with TB have atypical clinical manifestations and high mortality. Age, hypoalbuminemia, CKD stage 4-5, and HD were independent predictors of mortality.

Citing Articles

Effect of chronic kidney disease on adverse drug reactions to anti-tubercular treatment: a retrospective cohort study.

Datta D, Rao I, Prabhu A, Nagaraju S, Thunga G, Magazine R Ren Fail. 2024; 46(2):2392883.

PMID: 39165235 PMC: 11340219. DOI: 10.1080/0886022X.2024.2392883.


Non-communicable comorbidities in pulmonary tuberculosis and healthcare utilization: a cross-sectional study of 2021 Indonesian national health insurance data.

Prasiska D, Chapagain D, Osei K, Rajaguru V, Kang S, Kim T Arch Public Health. 2024; 82(1):127.

PMID: 39160626 PMC: 11331679. DOI: 10.1186/s13690-024-01352-y.


Epidemiology of tuberculosis in Kazakhstan: data from the Unified National Electronic Healthcare System 2014-2019.

Sakko Y, Madikenova M, Kim A, Syssoyev D, Mussina K, Gusmanov A BMJ Open. 2023; 13(10):e074208.

PMID: 37821138 PMC: 10582847. DOI: 10.1136/bmjopen-2023-074208.

References
1.
Wang J, Wang F, Liu S, Zhou M, Zhang L, Zhao M . Reduced Kidney Function, Albuminuria, and Risks for All-cause and Cardiovascular Mortality in China: A Population-based Cohort Study. BMC Nephrol. 2017; 18(1):188. PMC: 5463353. DOI: 10.1186/s12882-017-0603-9. View

2.
Cheng K, Liao K, Lin C, Liu C, Lai S . Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy: A cohort study in Taiwan. Medicine (Baltimore). 2018; 97(39):e12550. PMC: 6181567. DOI: 10.1097/MD.0000000000012550. View

3.
Kim E, Lee W, Jeong W, Choi H, Jung I, Ahn J . Chronic kidney disease with genitourinary tuberculosis: old disease but ongoing complication. BMC Nephrol. 2018; 19(1):193. PMC: 6090963. DOI: 10.1186/s12882-018-0994-2. View

4.
Ezer N, Benedetti A, Darvish-Zargar M, Menzies D . Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis. 2013; 17(4):447-55. DOI: 10.5588/ijtld.11.0766. View

5.
Saito N, Yoshii Y, Kaneko Y, Nakashima A, Horikiri T, Saito Z . Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. BMC Infect Dis. 2019; 19(1):374. PMC: 6498605. DOI: 10.1186/s12879-019-4010-7. View